Key facts
- AviadoBio’s last known valuation is $181.8M (Oct 2024).
- It has raised $149.1M; the latest was Later Stage VC ($31.2M) in Mar 2026.
- Notable investors include New Enterprise Associates, F-Prime Capital, Johnson & Johnson JJDC, SV Health Investors, EQT Life Sciences — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for AviadoBio
- ·The full record, as it builds
Funding rounds
No funding rounds for AviadoBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AviadoBio
Developer of transformative gene therapies designed to transform people living with devastating neurodegenerative diseases. The company's platform combines diseases such as frontotemporal dementia and amyotrophic lateral sclerosis with a deep understanding of the brain and a suite of proprietary gene therapies to overcome the challenges of delivering the right drug to the right place, enabling patients to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 65
- Website
- aviadobio.com/
- Ownership
- Privately Held (backing)
AviadoBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AviadoBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AviadoBio in its N-PORT filings yet. We sweep new filings monthly.